| Literature DB >> 28161578 |
Wenqian Tao1, Brett L Hurst2, Akhilesh Kumar Shakya1, Md Jasim Uddin1, Rohan S J Ingrole1, Mayra Hernandez-Sanabria3, Ravi P Arya3, Lynn Bimler3, Silke Paust3, E Bart Tarbet2, Harvinder Singh Gill4.
Abstract
The extracellular domain of influenza A ion channel membrane matrix protein 2 (M2e) is considered to be a potential candidate to develop a universal influenza A vaccine. However poor immunogenicity of M2e presents a significant roadblock. We have developed a vaccine formulation comprising of the consensus M2e peptide conjugated to gold nanoparticles (AuNPs) with CpG as a soluble adjuvant (AuNP-M2e + sCpG). We demonstrate that intranasal delivery of AuNP-M2e + sCpG in mice induces lung B cell activation and robust serum anti-M2e immunoglobulin G (IgG) response, with stimulation of both IgG1 and IgG2a subtypes. Using Madin-Darby canine kidney (MDCK) cells infected with A/California/04/2009 (H1N1pdm) pandemic strain, or A/Victoria/3/75 (H3N2), or the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1) as immunosorbants we further show that the antibodies generated are also capable of binding to the homotetrameric form of M2 expressed on infected cells. Lethal challenge of vaccinated mice with A/California/04/2009 (H1N1pdm) pandemic strain, A/Victoria/3/75 (H3N2), and the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1) led to 100%, 92%, and 100% protection, respectively. Overall, this study helps to lay the foundation of a potential universal influenza A vaccine.Entities:
Keywords: Adjuvants; CpG; Gold nanoparticles; Influenza vaccine; Intranasal vaccination; M2e; Universal influenza vaccine
Mesh:
Substances:
Year: 2017 PMID: 28161578 PMCID: PMC5572660 DOI: 10.1016/j.antiviral.2017.01.021
Source DB: PubMed Journal: Antiviral Res ISSN: 0166-3542 Impact factor: 5.970